The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Ascertaining the mechanisms of resistance to KRASG12C inhibitors
Liza Villaruz, MD, University of Pittsburgh, Pittsburgh, PA, comments on the potential mechanisms of resistance to KRASG12C inhibitors during the treatment of patients with non-small cell lung cancer (NSCLC). Second site mutations as well as activation of bypass pathways are potential causes of resistance which can reduce treatment options for patients. Incorporating SHP2 inhibitors may prevent resistance as well treat existing cases of KRASG12C resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL
